Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100

Zoetis Inc. (ZTS) Free cash flow margin

Alert me on Free cash flow margin

Zoetis Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 24.4%, up 0.3 percentage points from fiscal 2025 (24.1%). Over the past ten years it has ranged from 9.28% (fiscal 2015) to 25.9% (fiscal 2018); the current reading is higher than 73% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.

Free cash flow margin, annual

Embed this chart

Annual newest first

Period Free cash flow margin Change (points)
FY2025 24.1% (0.71)
FY2024 24.8% 5.86
FY2023 19.0% 2.55
FY2022 16.4% (5.93)
FY2021 22.4% (3.03)
FY2020 25.4% 3.72
FY2019 21.7% (4.23)
FY2018 25.9% 4.05
FY2017 21.8% 9.83
FY2016 12.0% 2.73

Against its own ten years

Low 9.28% High 25.9%
Ten-year median 21.8%
Current reading's percentile 73

Free cash flow margin against peers

What Free cash flow margin is

Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.

(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue

The full definition of Free cash flow margin →

More on ZTS